Clinical trials
Terminated Ovarian Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
307 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 4 |
| 2002 | 5 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 5 |
| 2006 | 16 |
| 2007 | 16 |
| 2008 | 8 |
| 2009 | 11 |
| 2010 | 11 |
| 2011 | 9 |
| 2012 | 9 |
| 2013 | 3 |
| 2014 | 8 |
| 2015 | 19 |
| 2016 | 15 |
| 2017 | 22 |
| 2018 | 17 |
| 2019 | 18 |
| 2020 | 19 |
| 2021 | 19 |
| 2022 | 19 |
| 2023 | 9 |
| 2024 | 10 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 307 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gynecologic Oncology Group | 18 |
| National Cancer Institute (NCI) | 13 |
| M.D. Anderson Cancer Center | 12 |
| Pfizer | 12 |
| Masonic Cancer Center, University of Minnesota | 8 |
| Dana-Farber Cancer Institute | 7 |
| Mayo Clinic | 5 |
| Novartis Pharmaceuticals | 5 |
| Seagen Inc. | 5 |
| OHSU Knight Cancer Institute | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 307 |
| Fallopian Tube Neoplasms | 85 |
| Carcinoma, Ovarian Epithelial | 60 |
| Breast Neoplasms | 58 |
| Carcinoma, Non-Small-Cell Lung | 52 |
| Endometrial Neoplasms | 36 |
| Neoplasms | 32 |
| Colorectal Neoplasms | 31 |
| Melanoma | 30 |
| Pancreatic Neoplasms | 27 |
Trials
Showing 1 to 25 of 307. Each trial links to its page on Pharma Observatory.
207 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.